A 12-month Open-label, Multicenter Observation Study on the Occurrence of Major Adverse Cardiac Events (MACE) in Patients With Acute Myocardial Infarction (AMI) Receiving Pitavastatin/Valsartan Treatment
Latest Information Update: 05 Apr 2023
At a glance
- Drugs Pitavastatin/valsartan (Primary)
- Indications Essential hypertension; Hypercholesterolaemia; Hyperlipoproteinaemia type IIa; Hyperlipoproteinaemia type IIb; Myocardial infarction
- Focus Therapeutic Use
- Acronyms LAMISIII
- Sponsors JW Pharmaceutical
- 11 Apr 2021 Planned End Date changed from 31 Dec 2021 to 30 Jun 2022.
- 11 Apr 2021 Planned primary completion date changed from 31 Dec 2020 to 30 Jun 2022.
- 25 Feb 2020 New trial record